Company: PSTV
Filing Date: 2025-08-01
Form Type: DEFA14A
Source: 0001140361-25-028381
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-01
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12

| PLUS THERAPEUTICS, INC. |

(Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. PLUS THERAPEUTICS, INC. August 1, 2025 SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 7, 2025 EXPLANATORY NOTE This supplement (the “Supplement”) to the definitive proxy statement filed by Plus Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission on July 21, 2025 (the “Proxy Statement”) relating to the Company’s virtual annual meeting to be held at 9:00 AM, Eastern Time, on Thursday, August 7, 2025 (the “Annual Meeting”) is being filed solely to correct an inadvertent error with respect to the description of the voting standard for Proposal 3 – The Reverse Stock Split Proposal (the “Reverse Stock Split Proposal”). Except as specifically supplemented by the information contained below, all information set forth in the Proxy Statement remains unchanged. The paragraph under the heading “Required Vote” on page 48 of the Proxy Statement, which states the voting standard applicable to the Reverse Stock Split Proposal, is revised to read as follows: Required Vote The affirmative vote of a majority of all votes cast by the holders of shares of Common Stock entitled to vote will be required for approval. Abstentions and broker non-votes, if any, will have no effect on the outcome of this proposal. The